Streetbeat News

Analyst Ratings

IRON

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating for Disc Medicine (NASDAQ:IRON) and maintained a price target of $70.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:51 am

TLSI

Oppenheimer has initiated coverage on TriSalus Life Sciences (NASDAQ:TLSI) with an Outperform rating and set a price target of $10.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:49 am

PGR

Morgan Stanley analyst Bob Huang maintains an Overweight rating on Progressive (NYSE:PGR) and raises the price target from $260 to $300.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:47 am

BCYC

HC Wainwright & Co. has reiterated its Buy rating for Bicycle Therapeutics, maintaining a price target of $55.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:46 am

IOBT

Morgan Stanley analyst Matthew Harrison maintains an Overweight rating on IO Biotech and raises the price target from $4 to $6.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:45 am

GTLS

Morgan Stanley has upgraded Chart Industries (NYSE:GTLS) from Equal-Weight to Overweight, maintaining the price target at $175.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:43 am

ITOS

HC Wainwright & Co. has reiterated its Buy rating for ITeos Therapeutics, maintaining a price target of $46. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:42 am

RLAY

Relay Therapeutics shares rose after HC Wainwright & Co maintained a Buy rating and increased the price target from $18 to $19.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:42 am

WKC

Morgan Stanley has downgraded World Kinect (NYSE:WKC) from Equal-Weight to Underweight, while maintaining the price target at $28.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:37 am

CNTX

HC Wainwright & Co. has reiterated its Buy rating on Context Therapeutics (NASDAQ:CNTX) and maintained a price target of $6.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:37 am